At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 263 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
In Brief
A Phase 4 clinical trial evaluating Dapagliflozin and Dapagliflozin matching placebo for Chronic Heart Failure With Reduced Systolic Function. Completed, enrolled 263 participants across 25 sites.
Detailed Summary
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMar 2016
Primary CompletionJun 2019
TodayJul 2026
First PostedJan 12, 2016
Enrollment StartMar 3, 2016
Primary CompletionJun 28, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.5 years ago
Interventions
Dapagliflozindrug
Dapagliflozin matching placebodrug